Structure-Function of UDP-Glucuronosyltransferases
Structure-Function of UDP-Glucuronosyltransferases
批准号:
7666021
负责人:
Anna Radominska-Pandya
金额:
$26.19万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-06-01 至 2012-07-31
关键词:
Active SitesAffectAmino Acid MotifsAmino AcidsBase SequenceBindingBinding ProteinsBinding SitesC-terminalCarcinogensCatalysisCategoriesChemical StructureChemicalsDigestionDiseaseDrug CompoundingDrug InteractionsElementsEnzymesEvaluationFamilyGlucuronosyltransferaseGoalsHumanIndividualIonsKineticsLabelLigandsMalignant NeoplasmsMass Spectrum AnalysisMembraneMetabolicMetabolic BiotransformationMetalsMolecularMolecular ModelsN-terminalNuclear ReceptorsPharmaceutical PreparationsPharmacogeneticsPharmacotherapyPhasePhotoaffinity LabelsPhysiologicalPoisonProtein IsoformsProteinsProtocols documentationRecombinant ProteinsRecombinantsRegulationResearch PersonnelResourcesRiskRoleSignaling MoleculeSiteSite-Directed MutagenesisSpecificityStructural ProteinStructureStructure-Activity RelationshipSubstrate SpecificityTestingToxic Environmental SubstancesUGT1A1 geneUridine Diphosphate Glucuronic Acidbasecofactorcomputerizeddesignenvironmental chemicalinhibitor/antagonistinsightmRNA Expressionmolecular modelingmutantpolypeptideresearch studysugar nucleotide
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): UGTs are of particular physiological, pharmacological, and toxicological significance due to their involvement in biotransformation of the largest number of endogenous compounds, drugs, and environmental toxins of different chemical structures and origins of any phase II metabolizing enzyme. Moreover, some UGT substrates, which are nuclear receptor ligands, signaling molecules, important drugs, and environmental chemicals, can affect UGT mRNA expression and alter the activity of the UGT enzymes. There is a tremendous need for the understanding of the pharmacogenetics and drug interactions of chemicals that are substrates for and inducers of UGTs. Due to the lack of homogeneous proteins for structural studies, it was previously impossible to predict the molecular mechanism of glucuronidation required to understand the mechanistic aspects of UGT substrate specificity, inhibition, and drug-drug interactions. Now that homogeneous UGT proteins have been generated, studies identifying UGT active sites are proposed. Our central hypothesis is that the N-terminal domain of UGTs consists of distinct substrate recognition sequences (SRSs) that display specificity for classes of UGT substrates and, thus, determine the catalytic mechanism and substrate specificity of individual UGT isoforms. For the co- substrate active site, we hypothesize that the site of UDP/Mg2+ binding is localized in the highly conserved C-terminal end of the UGT molecule. Specifically, we postulate that a DxxD motif, conserved in all UGTs. is a major element of the UDP-GlcUA (co-substrate) binding site. These hypotheses will be tested by the following Specific Aims: 1. To identify and characterize the substrate recognition sequences of UGTs. 2. To identify and characterize the UDP-GlcUA binding site of UGTs. 3. To sequence photolabeled polypeptides by mass spectrometry. 4. To modify amino acid motifs of putative binding sites by site-directed mutagenesis and catalytically characterize the generated mutants. The information derived from the proposed studies will provide insight into the molecular mechanism of glucuronidation and will enhance our ability to predict and direct the metabolic transformation of both endogenous and exogenous substrates for UGTs. This information will be important for understanding specific interactions between endogenous substrates and drugs. It will also serve as a basis in the search for new drugs and inhibitors of specific UGT isoforms, thus affecting drug therapy, drug-drug interactions, and the risk of chemically-induced diseases, including cancer.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3109/03602530903209049
发表时间:
2010-02
期刊:
Drug metabolism reviews
影响因子:
5.9
作者:
[Radominska-Pandya A, Bratton SM, Redinbo MR, Miley MJ]
通讯作者:
Miley MJ
DOI:
10.3791/1542
发表时间:
2009-11-02
期刊:
Journal of visualized experiments : JoVE
影响因子:
--
作者:
[Di Fiori, Nicolas, Meller, Amit]
通讯作者:
Meller, Amit
Sulfaphenazole and α-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice.
磺胺苯唑和α-萘黄酮会减弱 K2/香料中合成大麻素 JWH-018 和 AM2201 的代谢。
DOI:
10.2174/187231280701131211151523
发表时间:
2013
期刊:
Drug metabolism letters
影响因子:
--
作者:
[Chimalakonda,KrishnaC, James,LauraP, Radominska-Pandya,Anna, Moran,JefferyH]
通讯作者:
Moran,JefferyH
A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.
JWH-018 的主要葡萄糖醛酸化代谢物是 CB1 受体的中性拮抗剂。
DOI:
10.1021/tx3000472
发表时间:
2012
期刊:
Chemical research in toxicology
影响因子:
4.1
作者:
[Seely,KathrynA, Brents,LisaK, Radominska-Pandya,Anna, Endres,GregoryW, Keyes,GregoryS, Moran,JefferyH, Prather,PaulL]
通讯作者:
Prather,PaulL
DOI:
10.2147/ijn.s17684
发表时间:
2011
期刊:
International journal of nanomedicine
影响因子:
8
作者:
[Karmakar A, Bratton SM, Dervishi E, Ghosh A, Mahmood M, Xu Y, Saeed LM, Mustafa T, Casciano D, Radominska-Pandya A, Biris AS]
通讯作者:
Biris AS
共 7 条
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6940862
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6645333
-
项目类别:
-
资助金额:$27.51万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6947572
-
项目类别:
-
资助金额:$5.35万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6947533
-
项目类别:
-
资助金额:$5.23万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6479759
-
项目类别:
-
资助金额:$33.9万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
Glucuronidation of Fatty Acids by Human ER & Nuclear UGT
-
批准号:6787636
-
项目类别:
-
资助金额:$27.51万
-
财政年份:2002
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:6381608
-
项目类别:
-
资助金额:$24.79万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:6177931
-
项目类别:
-
资助金额:$26.58万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:2893266
-
项目类别:
-
资助金额:$23.05万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
HUMAN HEPATIC & INTESTINAL UDP GLUCURONOSYLTRANSFERASES
-
批准号:6524487
-
项目类别:
-
资助金额:$25.02万
-
财政年份:1999
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2749611
-
项目类别:
-
资助金额:$21.78万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2905938
-
项目类别:
-
资助金额:$22.43万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2402833
-
项目类别:
-
资助金额:$21.14万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
RETINOID UDP-GLUCURONOSYLTRANSFERASES
-
批准号:6177658
-
项目类别:
-
资助金额:$23.11万
-
财政年份:1997
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2150600
-
项目类别:
-
资助金额:$18.11万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2414898
-
项目类别:
-
资助金额:$18.93万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
Structure-Function of UDP-Glucuronosyltransferases
-
批准号:7143067
-
项目类别:
-
资助金额:$28.4万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2701173
-
项目类别:
-
资助金额:$18.83万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
STRUCTURE-FUNCTION OF HUMAN UDP-GLUCURONOSYLTRANSFERASES
-
批准号:2905742
-
项目类别:
-
资助金额:$19.56万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
Structure-Function of UDP-Glucuronosyltransferases
-
批准号:7272711
-
项目类别:
-
资助金额:$26.35万
-
财政年份:1996
-
负责人:Anna Radominska-Pandya
-
依托单位:
海外基金